Trials / Conditions / Warm Autoimmune Hemolytic Anemia

Warm Autoimmune Hemolytic Anemia

14 registered clinical trials studyying Warm Autoimmune Hemolytic Anemia — 3 currently recruiting.

Status	Trial	Sponsor	Phase
Recruiting	Study of Ianalumab in Adults With Primary Immune Thrombocytopenia (ITP) and Warm-antibody Autoimmune Hemolytic NCT07039422	Novartis Pharmaceuticals	Phase 2
Recruiting	Zanubrutinib in the Treatment of Relapsed/Refractory wAIHA NCT05922839	Chen Miao	Phase 2
Active Not Recruiting	A Study of Obexelimab in Patients With Warm Autoimmune Hemolytic Anemia (SApHiAre) NCT05786573	Zenas BioPharma (USA), LLC	Phase 3
Active Not Recruiting	An Open-label Study of Povetacicept in Participants With Autoimmune Cytopenias NCT05757570	Alpine Immune Sciences, Inc.	Phase 1 / Phase 2
Recruiting	Sirolimus in the Treatment of Refractory/Relapsed wAIHA NCT05925023	Peking Union Medical College Hospital	N/A
Withdrawn	Subcutaneous ALXN1830 in Adult Participants With Warm Autoimmune Hemolytic Anemia NCT04956276	Alexion Pharmaceuticals, Inc.	Phase 2
Withdrawn	ALXN1830 in Patients With Warm Autoimmune Hemolytic Anemia NCT04256148	Alexion Pharmaceuticals, Inc.	Phase 2
Terminated	To Assess the Efficacy and Safety of RVT-1401 in the Treatment of Warm Autoimmune Hemolytic Anemia (ASCEND-WAI NCT04253236	Immunovant Sciences GmbH	Phase 2
Withdrawn	Efficacy and Safety of Ixazomib and Dexamethasone Refractory Autoimmune Cytopenia NCT03965624	Assistance Publique - Hôpitaux de Paris	Phase 2
Active Not Recruiting	Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia NCT04119050	Janssen Research & Development, LLC	Phase 2 / Phase 3
Terminated	A Safety Study of SYNT001 in Participants With Warm Autoimmune Hemolytic Anemia (WAIHA) NCT03075878	Alexion Pharmaceuticals, Inc.	Phase 1 / Phase 2
Completed	Study to Assess the Safety, Tolerability, Efficacy and PK of APL-2 in Patients With Warm Type Autoimmune Hemol NCT03226678	Apellis Pharmaceuticals, Inc.	Phase 2
Completed	Rituximab in Auto-Immune Hemolytic Anemia NCT01181154	Assistance Publique - Hôpitaux de Paris	Phase 3
Temporarily Not Available	Post-trial Access for Nipocalimab in Participants With Warm Autoimmune Hemolytic Anemia (wAIHA) NCT05221619	Janssen Research & Development, LLC	—